Guidelines

PP.10 Cyclophosphamide prevents xenogeneic graft-versus-host disease, without abrogating graft-versus-leukemia effects

February 2020
PP.11 Origin and homeostasis of regulatory T cells in chronic Graft-versus-Host Disease

February 2020
PP.12 Analysis of differences in preventive measures after high-dose cyclophosphamide among Belgian stem cell transplant centres

February 2020
PP.13 Improvement of antibody-induced cell death in multiple myeloma

February 2020
PP.14 Immunophenotypic and molecular features of cuplike morphology in AML

February 2020
O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

February 2020
O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

February 2020
O.3 Palliative cytoreduction with low dose intravenous melphalan in patients with acute myeloid leukemia refractory to prior treatment

February 2020
O.4 An in-depth investigation of the causes of treatment failure in AML

February 2020
O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

February 2020

Top